References
- Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
- Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17
- Braunstahl GJ, Leo J, Thirlwell J, et al. Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Curr Med Res Opin 2011;27:761-7
- Lloyd A, Turk F, Leighton T, et al. Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ 2007;10:285-96
- Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149-53
- Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-76
- College voor zorgverzekeringen (CVZ). Guidelines for pharmacoeconomic research, updated version. Diemen, The Netherlands: College voor zorgverzekeringen, 2006. http://www.cvz.nl/binaries/content/documents/cvzinternet/en/documents/procedures/guidelines-pharmacoeconomic-research.pdf. Accessed August 1, 2011
- Centraal Bureau voor de Statistiek. Centraal Bureau voor de Statistiek [web page]. http://www.cbs.nl/nl-NL/menu/home/default.htm. Accessed December 14, 2010.
- Watson L, Turk F, James P, et al. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med 2007;101:1659-64
- Nederlandse Zorgautoriteit (NZA). Zoekprogramma DBC bedragen en overige bedragen medisch specialistische zorg door of vanwege de zorginstelling. Utrecht, The Netherlands: Nederlandse Zorgautoriteit (NZA), 2010. http://ctg.bit-ic.nl/Nzatarieven/top.do. Accessed December 20, 2010
- Hakkaart-van Roijen L, Tan SS, Bouwmans CCA. Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg (Geactualiseerde versie 2010). Diemen, The Netherlands: College voor Zorgverzekeringen, 2010. http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/rubriek+zorgpakket/cfh/handleiding-kostenonderzoek-2010.pdf. Accessed February 18, 2011
- Price Index. 2010. http://www.nza.nl/regelgeving/prijsindexcijfers/. Accessed December 14, 2010.
- Brusselle G, Michils A, Louis R, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009;103:1633-42
- Lamers LM, Stalmeier PF, McDonnell J, et al. [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. Ned Tijdschr Geneeskd 2005;149:1574-8
- Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22-7
- Lowhagen O, Ekstrom L, Holmberg S, et al. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243-7
- Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45-53
- Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011;180:637-41
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Cape Town, South Africa: Global Initiative for Asthma (GINA), 2011. http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html. Accessed August 1, 2011